Literature DB >> 24962903

Thrombosis in the uremic milieu--emerging role of "thrombolome".

Moshe Shashar1, Jean Francis, Vipul Chitalia.   

Abstract

Chronic kidney disease (CKD) is characterized by retention of a number of toxins, which unleash cellular damage. CKD environment with these toxins and a host of metabolic abnormalities (collectively termed as uremic milieu) is highly thrombogenic. CKD represents a strong and independent risk factor for both spontaneous venous and arterial (postvascular injury) thrombosis. Emerging evidence points to a previously unrecognized role of some of the prothrombotic uremic toxins. Here, we provide an overview of thrombosis in CKD and an update on indolic uremic toxins, which robustly increase tissue factor, a potent procoagulant, in several vascular cell types enhancing thrombosis. This panel of uremic toxins, which we term "thrombolome" (thrombosis and metabolome), represents a novel risk factor for thrombosis and can be further explored as biomarker for postvascular interventional thrombosis in patients with CKD.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24962903      PMCID: PMC4407993          DOI: 10.1111/sdi.12255

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  83 in total

1.  Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.

Authors:  D E Cutlip; D S Baim; K K Ho; J J Popma; A J Lansky; D J Cohen; J P Carrozza; M S Chauhan; O Rodriguez; R E Kuntz
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

2.  Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients.

Authors:  Akihiko Kato; Yuzo Suzuki; Takafumi Suda; Masako Suzuki; Michio Fujie; Takako Takita; Mitsuyoshi Furuhashi; Yukitaka Maruyama; Kingo Chida; Akira Hishida
Journal:  Hemodial Int       Date:  2010-10       Impact factor: 1.812

3.  Chronic kidney disease stages 1-3 increase the risk of venous thrombosis.

Authors:  G Ocak; M Verduijn; C Y Vossen; W M Lijfering; F W Dekker; F R Rosendaal; R T Gansevoort; B K Mahmoodi
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

4.  Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography.

Authors:  F C Schoebel; F Gradaus; K Ivens; P Heering; T W Jax; B Grabensee; B E Strauer; M Leschke
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

5.  Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.

Authors:  Tsuneo Deguchi; Sumio Ohtsuki; Masaki Otagiri; Hitomi Takanaga; Hiroshi Asaba; Shinobu Mori; Tetsuya Terasaki
Journal:  Kidney Int       Date:  2002-05       Impact factor: 10.612

6.  Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.

Authors:  Fellype C Barreto; Daniela V Barreto; Sophie Liabeuf; Natalie Meert; Griet Glorieux; Mohammed Temmar; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 8.237

7.  Characterization of uremic toxin transport by organic anion transporters in the kidney.

Authors:  Tsuneo Deguchi; Hiroyuki Kusuhara; Akira Takadate; Hitoshi Endou; Masaki Otagiri; Yuichi Sugiyama
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

8.  Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD.

Authors:  Ruben Poesen; Liesbeth Viaene; Kristin Verbeke; Kathleen Claes; Bert Bammens; Ben Sprangers; Maarten Naesens; Yves Vanrenterghem; Dirk Kuypers; Pieter Evenepoel; Björn Meijers
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 8.237

9.  Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.

Authors:  John M Lasala; David A Cox; David Dobies; Kenneth Baran; William B Bachinsky; Edwin W Rogers; Jeffrey A Breall; David H Lewis; Aijun Song; Ruth M Starzyk; Stephen R Mascioli; Keith D Dawkins; Donald S Baim
Journal:  Circ Cardiovasc Interv       Date:  2009-07-22       Impact factor: 6.546

10.  The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction.

Authors:  Suree Lekawanvijit; Sirinart Kumfu; Bing H Wang; Minako Manabe; Fuyuhiko Nishijima; Darren J Kelly; Henry Krum; Andrew R Kompa
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

View more
  22 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  Dialysis Vascular Access Intervention and the Search for Biomarkers.

Authors:  Karl A Nath
Journal:  J Am Soc Nephrol       Date:  2015-10-09       Impact factor: 10.121

3.  Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk.

Authors:  Moshe Shashar; Mostafa E Belghasem; Shinobu Matsuura; Joshua Walker; Sean Richards; Faisal Alousi; Keshab Rijal; Vijaya B Kolachalama; Mercedes Balcells; Minami Odagi; Kazuo Nagasawa; Joel M Henderson; Amitabh Gautam; Richard Rushmore; Jean Francis; Daniel Kirchhofer; Kumaran Kolandaivelu; David H Sherr; Elazer R Edelman; Katya Ravid; Vipul C Chitalia
Journal:  Sci Transl Med       Date:  2017-11-22       Impact factor: 17.956

Review 4.  Metabonomic biomarkers for risk factors of chronic kidney disease.

Authors:  Libing Ye; Wei Mao
Journal:  Int Urol Nephrol       Date:  2016-02-20       Impact factor: 2.370

5.  The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia.

Authors:  Sowmya Shivanna; Kumaran Kolandaivelu; Moshe Shashar; Mostafa Belghasim; Laith Al-Rabadi; Mercedes Balcells; Anqi Zhang; Janice Weinberg; Jean Francis; Michael P Pollastri; Elazer R Edelman; David H Sherr; Vipul C Chitalia
Journal:  J Am Soc Nephrol       Date:  2015-05-27       Impact factor: 10.121

Review 6.  The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease.

Authors:  Hai Ning Wee; Jian-Jun Liu; Jianhong Ching; Jean-Paul Kovalik; Su Chi Lim
Journal:  Am J Nephrol       Date:  2021-11-09       Impact factor: 3.754

7.  Indoleamine 2,3-dioxygenase-1, a Novel Therapeutic Target for Post-Vascular Injury Thrombosis in CKD.

Authors:  Joshua A Walker; Sean Richards; Stephen A Whelan; Sung Bok Yoo; Teresa L Russell; Nkiruka Arinze; Saran Lotfollahzadeh; Marc A Napoleon; Mostafa Belghasem; Norman Lee; Laura M Dember; Katya Ravid; Vipul C Chitalia
Journal:  J Am Soc Nephrol       Date:  2021-11       Impact factor: 10.121

Review 8.  Venous Thromboembolism in Kidney Diseases and Genetic Predisposition.

Authors:  Tingting Wu; Liang V Tang; Yu Hu
Journal:  Kidney Dis (Basel)       Date:  2022-04-11

9.  Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis.

Authors:  Mostafa Belghasem; Daniel Roth; Sean Richards; Marc Arthur Napolene; Joshua Walker; Wenqing Yin; Nkiruka Arinze; Chimera Lyle; Cheryl Spencer; Jean M Francis; Cristal Thompson; Christopher Andry; Stephen A Whelan; Norman Lee; Katya Ravid; Vipul C Chitalia
Journal:  Blood       Date:  2019-12-26       Impact factor: 25.476

10.  Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans.

Authors:  Vijaya B Kolachalama; Moshe Shashar; Faisal Alousi; Sowmya Shivanna; Keshab Rijal; Mostafa E Belghasem; Joshua Walker; Shinobu Matsuura; Gary H Chang; C Michael Gibson; Laura M Dember; Jean M Francis; Katya Ravid; Vipul C Chitalia
Journal:  J Am Soc Nephrol       Date:  2018-01-17       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.